Forte Biosciences, Inc. (FBRX)

NASDAQ: FBRX · IEX Real-Time Price · USD
1.08
-0.11 (-8.90%)
At close: May 16, 2022 4:00 PM
1.11
0.04 (3.26%)
After-hours:May 16, 2022 7:46 PM EDT
Market Cap15.87M
Revenue (ttm)n/a
Net Income (ttm)-19.47M
Shares Out14.76M
EPS (ttm)-1.55
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume325,534
Open1.18
Previous Close1.18
Day's Range1.06 - 1.18
52-Week Range1.06 - 43.57
Betan/a
AnalystsSell
Price Target3.57 (+232.1%)
Earnings DateMay 16, 2022

About FBRX

Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.

IndustryBiotechnology
CEOMartin Duvall
Employees5
Stock ExchangeNASDAQ
Ticker SymbolFBRX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for FBRX stock is "Sell." The 12-month stock price forecast is 3.57, which is an increase of 232.09% from the latest price.

Price Target
$3.57
(232.09% upside)
Analyst Consensus: Sell
Stock Forecasts

News

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Forte Biosciences, Inc....

LOS ANGELES--(BUSINESS WIRE)---- $FBRX #FBRX--ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Forte Biosciences, Inc.

8 months ago - Business Wire

INVESTIGATION REMINDER: The Schall Law Firm Announces It Is Investigating Claims Against Forte Biosciences, Inc. and ...

Los Angeles, California--(Newsfile Corp. - September 6, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Fo...

8 months ago - Newsfile Corp

Forte (FBRX) Posts Dismal Data on Atopic Dermatitis Candidate

Forte's (FBRX) mid-stage study on its lead candidate FB-401 to address the condition of atopic dermatitis fails to meet its primary goal and the company decides to discontinue the study further.

8 months ago - Zacks Investment Research

Why Forte Biosciences Stock Is Down Over 80% Today

Forte Biosciences (NASDAQ: FBRX) is tanking today after the company announced the clinical trial of FB-401 for the treatment of atopic dermatitis failed to meet statistical significance. “We are appreci...

8 months ago - Benzinga

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Forte Biosciences, Inc. - FBRX

NEW YORK, Sept. 3, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Forte Biosciences, Inc. ("Forte" or the "Company") (NASDAQ: FBRX).

8 months ago - PRNewsWire

A small biotech firm just plummeted 82% after abandoning a drug candidate due to failed phase 2 trial

The negative drug results led Chardan Capital Markets to slash its price target by 96% to $4 from $105.

8 months ago - Business Insider

Why Forte Biosciences Stock Is Imploding Today

The company announced dismal results from a phase 2 study of its only pipeline candidate.

8 months ago - The Motley Fool

Forte Biosciences stock plunges more than 80% after 'disappointing' trial results of atopic dermatitis treatment

Shares of Forte Biosciences Inc. FBRX, -4.45% plummeted 81.2% on heavy volume toward a record low in premarket trading Friday, after the biopharmaceutical company said it will no longer advance its lead...

8 months ago - Market Watch

Forte Biosciences Just Plummeted 80%: Here's Why

A biopharmaceutical company focused on the development of dermatology treatments saw a sharp drop after hours Thursday. What Happened: The clinical trial of Forte Biosciences (NASDAQ: FBRX) lead drug FB...

8 months ago - Benzinga

Clinical Trial of FB-401 For the Treatment of Atopic Dermatitis Fails to Meet Statistical Significance

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced that topline data from its Phase 2 clinical tr...

8 months ago - Business Wire

Forte Biosciences, Inc. to Review the Second Quarter 2021 Results and Expects to Announce Topline Data From Phase 2 C...

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, will review the second quarter results and, based on the proje...

9 months ago - Business Wire

Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced the issuance of an equity inducement award as ...

9 months ago - Business Wire

Implied Volatility Surging for Forte Biosciences (FBRX) Stock Options

Investors need to pay close attention to for Forte Biosciences (FBRX) stock based on the movements in the options market lately.

10 months ago - Zacks Investment Research

Forte Biosciences, Inc. Announces First Quarter 2021 Results and Provides a General Business Update

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company announces first quarter 2021 results and provides a general bus...

1 year ago - Business Wire

Forte Biosciences, Inc. to Announce First Quarter 2021 Results and Provide a General Business Update

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, will be providing first quarter 2021 results and a general bus...

1 year ago - Business Wire

Forte Biosciences, Inc. Announces 4Q and Full Year 2020 Results and Provides a General Business Update

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company announces fourth quarter and full year 2020 results and provide...

1 year ago - Business Wire

Forte Biosciences, Inc. to Announce 4Q and Full Year 2020 Results and Provide a General Business Update

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, will be providing 4Q and full year 2020 results and provide a ...

1 year ago - Business Wire

Forte Biosciences, Inc. to Present at the Chardan Annual Microbiome Medicines Summit on March 8th

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, announced today that Paul Wagner, Ph.D., CEO of Forte Bioscien...

1 year ago - Business Wire

Forte Biosciences, Inc. to Present at the Cowen Annual Health Care Conference on March 1st

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, announced today announced that Paul Wagner, Ph.D., CEO of Fort...

1 year ago - Business Wire

Forte Biosciences, Inc. to Present at the Evercore ISI 3rd Annual HealthCONx Conference on December 3rd

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, announced today announced that Paul Wagner, Ph.D., CEO of Fort...

1 year ago - Business Wire

Forte Biosciences, Inc. to Present at the Stifel 2020 Virtual Healthcare Conference on November 18th

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, announced today announced that Paul Wagner, Ph.D., CEO of Fort...

1 year ago - Business Wire

Forte Biosciences, Inc. Announces Third Quarter 2020 Results and Provides General Business Update

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced third quarter 2020 financial results and provi...

1 year ago - Business Wire

Forte Biosciences, Inc. to Announce Third Quarter 2020 Results on November 9

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced that it will release third quarter 2020 result...

1 year ago - Business Wire

Forte Biosciences Announces Closing of $46.0 Million Public Offering of Common Stock and Full Exercise of Underwriter...

TORRANCE, Calif.--(BUSINESS WIRE)--Forte Biosciences, Inc. (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, announced today the closing of its previously announced underwritten public offerin...

1 year ago - Business Wire

Forte Biosciences Announces Pricing of $40.0 Million Public Offering of Common Stock

TORRANCE, Calif.--(BUSINESS WIRE)--FORTE BIOSCIENCES ANNOUNCES PRICING OF $40.0 MILLION PUBLIC OFFERING OF COMMON STOCK

1 year ago - Business Wire